Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 9, Issue 3-4, Pages 127-132
http://dx.doi.org/10.1080/13577140500287024

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)

1Instituto Valenciano de Oncología, Valencia, Spain
2Hospital de San Pau, Barcelona, Spain
3Hospital Son Dureta, Palma de Mallorca, Spain
4Instituto Catalán de Oncología, Barcelona, Spain
5Hospital Virgen del Rocío, Sevilla, Spain
6Hospital San Carlos, Madrid, Spain
7Hospital Germán Trías y Pujol, Badalona, Spain
8Hospital Provincial de Conxo, Santiago de Compostela, Spain
9Hospital Clínico, Zaragoza, Spain
10Hospital Universitario de Canarias, La Laguna, Spain
11Biostatician, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Spain
12Data Manager, Hospital de San Pau, Barcelona, Spain
13Servicio de Oncología Médica, Hospital Central de Asturias (IUOPA), Julián Clavería s/n, Oviedo 33005 , Spain

Received 8 April 2005; Revised 5 July 2005; Accepted 22 July 2005

Copyright © 2005 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

A. Poveda, A. López-Pousa, J. Martín, et al., “Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS),” Sarcoma, vol. 9, no. 3-4, pp. 127-132, 2005. https://doi.org/10.1080/13577140500287024.